Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carisbamate Bioavailability and Food Effect Study
NCT04520360Phase 1Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Aug 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of carisbamate in Lennox-Gastaut syndrome (LGS), sponsored by SK Life Science, Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 35 days and Pharmacokinetic Parameters (AUC, Cmax, Tmax). Started Aug 2020; status: completed.
02
Drugs
carisbamate
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT04520360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520360.